Description: For people currently using Rebif to control multiple sclerosis, this study will evaluate their quality of life during the transition to a new investigational formulation of Rebif. Study medication will be provided at no cost to participants, who must be ages 18 to 60, diagnosed with a relapsing form of multiple sclerosis, and currently taking Rebif injections three times per week for at least the past six months.